This article is more than 5 years old. Information may no longer be current.
Regeneron reports significantly greater gains in BCVA
Eylea demonstrated “significantly greater improvement” in mean change in best corrected visual acuity from baseline compared with Avastin and Lucentis injection in a National Institutes of Health-sponsored study, according to a Regeneron press release.
The Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study in patients with diabetic macular edema (Protocol T) included 660 patients randomly assigned to treatment with Eylea (aflibercept, Regeneron) 2 mg, Avastin (bevacizumab, Genentech) 1.25 mg, or Lucentis (ranibizumab, Genentech) 0.3 mg.
Data indicated the median number of injections using the protocol-specified retreatment regimen was one fewer in patients treated with aflibercept compared with bevacizumab and ranibizumab, according to the press release.
Moreover, fewer patients in the aflibercept group received criteria-based macular laser treatments compared with those treated with bevacizumab or ranibizumab.
The rate of arterial thromboembolic events (ie, non-fatal stroke, non-fatal myocardial infarction and vascular death) was 2% in the aflibercept group, 4% in the bevacizumab group and 5% in the ranibizumab group, according to the press release.
Overall, more cardiovascular events occurred in the ranibizumab group compared with the aflibercept group and the bevacizumab group.